Skip to main content

Table 1 Patient and transplant characteristics

From: Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation

Characteristics

 n = 63

Patient age, median (range), y

42 (16–65)

Diagnosis at transplant, no. (%)

Malignant diseases

  Acute myeloid leukemia

23 (36.5%)

  Chronic myeloid leukemia

9 (14.3%)

  Acute lymphoblastic leukemia

9 (14.3%)

  Chronic lymphocytic leukemia

4 (6.3%)

  Multiple myeloma

2 (3.2%)

  Non-Hodgkin lymphoma

3 (4.8%)

  Hodgkin lymphoma

2 (3.2%)

  Myelodysplastic syndrome

4 (6.3%)

Non-malignant diseases

  Severe aplastic anemia

4 (6.3%)

  Paroxysmal nocturnal hemoglobinuria

3 (4.8%)

Donor age, median (range), y

39 (6–65)

Patient gender (donor/recipient), n. (%)

  Male/male

23 (36.5%)

  Male/female

10 (15.9%)

  Female/male

13 (20.6%)

  Female/female

17 (27%)

Donor type, no. (%)

  HLA-identical related

61 (96.8%)

  HLA-matched unrelated

2 (3.2%)

Conditioning regimen, no. (%)

  High dose

46 (73%)

  Low dose

17 (27%)

Source of stem cells, no. (%)

  Bone marrow

23 (36.5%)

  Mobilized blood

40 (63.5%)

GVHD prophylaxis, no. (%)

  Cyclosporine plus methotrexate

49 (77.7%)

  Cyclosporine plus mycophenolate mofetil

14 (22.3%)

Acute GVHD, no. (%)

17 (27%)

  Grade 0-I

46 (73%)

  Grade II-IV

17 (27%)

Donor/recipient CMV serologic status, n° (%)

  IgG +/IgG+

55 (87.2%)

  IgG +/IgG -

3 (4.8%)

  IgG -/IgG -

2 (3.2%)

  IgG-/igG+

2 (3.2%)

  Not determined

1 (1.6%)

  1. GVDH graft-versus-host disease, CMV cytomegalovirus.